The Angiotensin Receptor Blockers (ARBs) Global Market Report 2023, provides comprehensive information on the angiotensin receptor blockers (arbs) market across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten year historic period – 2010-2021, and a ten year forecast period – 2023-2032.

Learn More On The Angiotensin Receptor Blockers (ARBs) Market’s Growth:
https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

Notably, one discernible trend that has emerged is the prominence of product innovation as a driving force within the ARBs industry. Prominent companies operating in this sector have diligently channeled their efforts towards pioneering solutions to fortify their market standing.

A case in point is Novartis AG, a Switzerland-based pharmaceutical titan, which made significant strides in this regard in February 2021 with the launch of Entresto (sacubitril/valsartan). Entresto, having secured an expanded indication from the United States Food and Drug Administration, is instrumental in mitigating the risk of cardiovascular death and hospitalization for adult patients afflicted with chronic heart failure. This clinical breakthrough is most perceptible in patients with a left ventricular ejection fraction (LVEF) lower than the norm. Of paramount significance is the fact that Entresto is the inaugural therapy in the United States to address the full spectrum of guideline-defined heart failure, catering to those with heart failure featuring reduced ejection fraction (HFrEF) and those with preserved ejection fraction (HFpEF).

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample_request?id=8943&type=smp

A salient trend within this industry is the impetus on product innovation, as major industry players actively pursue innovative solutions to bolster their market standing. Notably, in February 2021, Novartis AG, a distinguished Swiss pharmaceutical entity, introduced Entresto (sacubitril/valsartan). This revolutionary product garnered an expanded endorsement from the United States Food and Drug Administration (FDA) for its effectiveness in reducing the risk of cardiovascular death and hospitalization in adult patients grappling with chronic heart failure. It's worth noting that the clinical benefits of Entresto are most pronounced among patients exhibiting a lower-than-normal left ventricular ejection fraction (LVEF). Additionally, it is the solitary therapy in the United States designed to address patients with guideline-defined heart failure, encompassing both individuals with heart failure with reduced ejection fraction (HFrEF) and those afflicted with heart failure with preserved ejection fraction (HFpEF). This augments the therapeutic arsenal available to healthcare professionals, enhancing the prospects of better patient outcomes.

The angiotensin receptor blockers (arbs) market is segmented:
1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan
2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications
3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers

North America was the largest region in the angiotensin receptor blockers (arbs) market in 2022.

The table of contents in TBRC’s angiotensin receptor blockers (arbs) market report includes
1. Executive Summary
2. Angiotensin Receptor Blockers (ARBs) Market Characteristics
3. Angiotensin Receptor Blockers (ARBs) Market Trends And Strategies
4. Angiotensin Receptor Blockers (ARBs) Market - Macro Economic Scenario
5. Angiotensin Receptor Blockers (ARBs) Market Size And Growth

.....

26. Africa Angiotensin Receptor Blockers (ARBs) Market
27. Angiotensin Receptor Blockers (ARBs) Market Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions In The Angiotensin Receptor Blockers (ARBs) Market
29. Angiotensin Receptor Blockers (ARBs) Market Future Outlook and Potential Analysis
30. Appendix

Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries. Through the report businesses can gain a thorough understanding of the market’s size, growth rate, major drivers and leading players.

Recent Reports:
https://topprnews.com/global-flexible-foam-market-size/
https://topprnews.com/flexible-pipe-market-report/
https://topprnews.com/foam-blowing-agents-market-size/
https://goodprnews.com/global-flexible-foam-market-size/
https://goodprnews.com/flexible-pipe-market-report/
https://goodprnews.com/foam-blowing-agents-market-size/

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model